Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials.
Shah SJ, van Walraven C, Jeon SY, Boscardin J, Hobbs FDR, Connolly SJ, Ezekowitz MD, Covinsky KE, Fang MC, Singer DE.
Shah SJ, et al. Among authors: van walraven c.
Circ Cardiovasc Qual Outcomes. 2024 Apr;17(4):e010269. doi: 10.1161/CIRCOUTCOMES.123.010269. Epub 2024 Mar 25.
Circ Cardiovasc Qual Outcomes. 2024.
PMID: 38525596
METHODS: We conducted a secondary analysis of 12 randomized controlled trials that randomized patients with atrial fibrillation to vitamin K antagonists (VKAs) or either placebo or antiplatelets. For each participant, we estimated the absolute risk reduction (ARR) of VKAs …
METHODS: We conducted a secondary analysis of 12 randomized controlled trials that randomized patients with atrial fibrillation to vitamin …